Effect of Dietary Protein Source on Phosphaturia, PTH and FGF23 in Patients With CKD 3 and 4
NCT ID: NCT00764816
Last Updated: 2011-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
9 participants
INTERVENTIONAL
2008-10-31
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
NCT01161407
Low-Phosphate Diet and Fibroblast Growth Factor-23 Level
NCT03367338
Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease
NCT03108222
The Impact of a Low or High Phosphate Diet on Phosphate and Calcium Excretion in Healthy People
NCT04013776
Analysis of Calcium Balance in Chronic Kidney Disease
NCT00974532
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In healthy individuals, there is variation throughout the day (diurnal) in serum phosphorus and urine phosphorus excretion, but in dialysis patients, this variability appears to be lost. No data exists for patients with stage 3 and 4 (pre-dialysis) CKD. Intestinal phosphorus absorption is also dependent on bioavailability (amount of free phosphorus available to be absorbed), which differs depending on the protein source, as the phosphorus in grain/soy diets is less bioavailable than that from protein from animal/casein protein source. In our animal model of CKD, these differences in bioavailability impact urinary phosphorus excretion and serum levels of FGF-23, but not PTH. As phosphaturia, PTH, and FGF23 may become important end points for future clinical trials, understanding diurnal variability and the relationship to diet in patients with CKD 3 and 4 with normal serum phosphorus levels is critical. We hypothesize that dietary protein source will affect the hormonal response and diurnal phosphorus homeostasis in advanced CKD. To test this hypothesis, we will examine the following specific aims in a population of CKD stage 3 and 4 subjects from the Indiana University Affiliated Nephrology Clinics and determine
1. if the dietary protein source affects fasting serum and urinary phosphorus excretion
2. if the protein source affects post prandial changes in serum and urinary phosphorus in patients
3. if changes in plasma FGF23 and PTH correlate with urinary phosphorus excretion in response to different protein sources.
We will conduct a cross over study to assess blood and urine after one week of a diet that differs only in the source of the protein (and thus the bioavailability of phosphorus).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 grain (soy) protein diet:
The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
grain (soy) protein diet
The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
2 casein (meat) protein diet
The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
casein (meat) protein diet
The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
grain (soy) protein diet
The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
casein (meat) protein diet
The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* eGFR 20-45 by modified MDRD equation
* protein/creatinine ratio \<5
* blood pressure \<150/95
* not taking calcium binder or supplements, vitamin D, or phosphate binders
* normal serum phosphorus and calcium corrected for albumin and intact PTH \<100pg/ml
* medically stable
* able to give informed consent and come for all visits
Exclusion Criteria
* medically unstable
* unable to tolerate diets
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Indiana University Department of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sharon M Moe, MD
Role: PRINCIPAL_INVESTIGATOR
Indiana University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Indiana University School of Medicine
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol. 2011 Feb;6(2):257-64. doi: 10.2215/CJN.05040610. Epub 2010 Dec 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0807-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.